Category Regulatory

BMS’s Anti-Tau Antibody PRX005 Gets FDA Fast Track for Alzheimer’s

BMS’s Anti-Tau Antibody PRX005 Gets FDA Fast Track for Alzheimer’s

Prothena Corporation plc announced that its partner, Bristol Myers Squibb (BMS), has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for BMS-986446 (PRX005), an investigational anti-microtubule binding region-tau (anti-MTBR-tau) antibody currently in Phase 2 clinical development…

Read MoreBMS’s Anti-Tau Antibody PRX005 Gets FDA Fast Track for Alzheimer’s